Last reviewed · How we verify

Erythromycin, Azithromycin , Clarithromycin — Competitive Intelligence Brief

Erythromycin, Azithromycin , Clarithromycin (Erythromycin, Azithromycin , Clarithromycin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Macrolide antibiotic. Area: Infectious Disease.

marketed Macrolide antibiotic Bacterial 50S ribosomal subunit Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Erythromycin, Azithromycin , Clarithromycin (Erythromycin, Azithromycin , Clarithromycin) — Baqiyatallah Medical Sciences University. These macrolide antibiotics inhibit bacterial protein synthesis by binding to the 50S ribosomal subunit.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Erythromycin, Azithromycin , Clarithromycin TARGET Erythromycin, Azithromycin , Clarithromycin Baqiyatallah Medical Sciences University marketed Macrolide antibiotic Bacterial 50S ribosomal subunit
AzaSite Eye Drops AzaSite Eye Drops Merck Sharp & Dohme LLC marketed Macrolide antibiotic Bacterial 50S ribosomal subunit
Clindamycin Gel (clindamycin ) Clindamycin Gel (clindamycin ) Stiefel, a GSK Company marketed Lincosamide antibiotic Bacterial 50S ribosomal subunit
Tedizolid IV Tedizolid IV University of Southern California marketed Oxazolidinone antibiotic Bacterial 50S ribosomal subunit
Tedizolid PO Tedizolid PO University of Southern California marketed Oxazolidinone antibiotic Bacterial 50S ribosomal subunit
IV azithromycin IV azithromycin Pfizer marketed Macrolide antibiotic Bacterial 50S ribosomal subunit
Zmax Zmax Pfizer marketed Macrolide antibiotic Bacterial 50S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Macrolide antibiotic class)

  1. Pfizer · 6 drugs in this class
  2. Grünenthal GmbH · 4 drugs in this class
  3. Merck Sharp & Dohme LLC · 3 drugs in this class
  4. University of Taubate · 2 drugs in this class
  5. Lihir Medical Centre · 2 drugs in this class
  6. Thomas Jefferson University · 2 drugs in this class
  7. Copenhagen Studies on Asthma in Childhood · 1 drug in this class
  8. Ain Shams Maternity Hospital · 1 drug in this class
  9. Celltrion · 1 drug in this class
  10. London School of Hygiene and Tropical Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Erythromycin, Azithromycin , Clarithromycin — Competitive Intelligence Brief. https://druglandscape.com/ci/erythromycin-azithromycin-clarithromycin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: